Moleac launches CognivAiD™, a novel targeted product for vascular dementia
GlobeNewswire
January 16, 2023
CognivAiD provides a long-awaited option to fulfil the unmet needs of patients with vascular dementia. CognivAiD demonstrated significant and clinically meaningful disease-modifying benefits in clinical trials based on VaDAS-Cog and ADCS-CGIC scales, with a favourable safety profile.CognivAiD has...